{"id":495,"date":"2026-05-14T07:34:26","date_gmt":"2026-05-14T07:34:26","guid":{"rendered":"https:\/\/tampamovingjournal.com\/?p=495"},"modified":"2026-05-14T07:34:26","modified_gmt":"2026-05-14T07:34:26","slug":"glioblastoma-vaccine-shows-early-promise-in-boosting-survival","status":"publish","type":"post","link":"https:\/\/tampamovingjournal.com\/?p=495","title":{"rendered":"Glioblastoma vaccine shows early promise in boosting survival"},"content":{"rendered":"
\n
\"\"<\/figure>\n article<\/span><\/div>

Trial participant Kim Garland (left) reviews a scan with the study\u2019s primary investigator, Tanner Johanns, MD, PhD, a WashU Medicine oncologist. (Courtesy: Scott Garland)<\/span> <\/p>

Read more Can tarantula venom cure anxiety? Tampa teen\u2019s AI research wins Florida Invention Convention<\/a><\/p> <\/div><\/div> <\/div>

A personalized vaccine for glioblastoma, an aggressive and incurable brain cancer, appears safe and may extend survival in some patients, according to an early-stage clinical trial co-led by researchers at Washington University School of Medicine in St. Louis.<\/p>

Why you should care:<\/p>

The experimental treatment triggered strong and broad immune responses and was linked to longer recurrence-free survival after surgery in a subset of patients. Among those with particularly aggressive disease, the vaccine caused no serious side effects and was associated with improved overall survival compared with historical outcomes following standard surgery and chemo-radiotherapy. One patient remains cancer-free nearly five years after diagnosis.<\/p>

<\/div>

RELATED: <\/strong>\u2018Miracle fruit\u2019 may help cancer patients fight chemo-related weight loss<\/strong><\/p>

The findings come from a phase 1 trial conducted at Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine and were published May 12 in Nature Cancer<\/i>. The study was led in collaboration with Mass General Brigham and Geneos Therapeutics, a Philadelphia-based biotechnology company.<\/p>

What they’re saying:<\/p>

“We are extremely encouraged by these results,” Tanner M. Johanns, MD, PhD, lead author, said in a news release. “This kind of vaccine is a first for glioblastoma, and it is exciting to think how we can leverage this individualized therapeutic DNA cancer vaccine platform to make a positive impact on the lives of patients who are fighting this disease. Additionally, combination therapies leveraging this personalized platform are currently being investigated at WashU to test if outcomes may be improved further.”<\/p>

RELATED: <\/strong>New drug significantly extends survival in advanced pancreatic cancer trial<\/strong><\/p>